Compare VNDA & NXJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VNDA | NXJ |
|---|---|---|
| Founded | 2002 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.0M | 503.5M |
| IPO Year | 2005 | N/A |
| Metric | VNDA | NXJ |
|---|---|---|
| Price | $7.84 | $12.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $14.90 | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 114.8K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.27% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $216,105,000.00 | N/A |
| Revenue This Year | $21.50 | N/A |
| Revenue Next Year | $38.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.72 | N/A |
| 52 Week Low | $3.81 | $11.01 |
| 52 Week High | $9.60 | $12.90 |
| Indicator | VNDA | NXJ |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 32.52 |
| Support Level | $4.25 | $11.24 |
| Resistance Level | $8.29 | $12.37 |
| Average True Range (ATR) | 0.53 | 0.09 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 63.39 | 14.85 |
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The company invests a majority of its managed assets in securities rated, at the time of investment, investment grade or, if the bonds are unrated, are judged by the manager to be of comparable quality.